VMD vs. CO, ARA, MRAI, OTRK, MGRX, BRTX, GBNHF, CORBF, TVTY, and PGNY
Should you be buying Viemed Healthcare stock or one of its competitors? The main competitors of Viemed Healthcare include Global Cord Blood (CO), American Renal Associates (ARA), Marpai (MRAI), Ontrak (OTRK), Mangoceuticals (MGRX), BioRestorative Therapies (BRTX), Greenbrook TMS (GBNHF), Global Cord Blood (CORBF), Tivity Health (TVTY), and Progyny (PGNY).
Viemed Healthcare (NASDAQ:VMD) and Global Cord Blood (NYSE:CO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability, valuation and community ranking.
Viemed Healthcare has a net margin of 5.32% compared to Global Cord Blood's net margin of 0.00%. Viemed Healthcare's return on equity of 9.32% beat Global Cord Blood's return on equity.
74.2% of Viemed Healthcare shares are owned by institutional investors. 20.0% of Viemed Healthcare shares are owned by insiders. Comparatively, 0.5% of Global Cord Blood shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Global Cord Blood has higher revenue and earnings than Viemed Healthcare. Global Cord Blood is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.
In the previous week, Viemed Healthcare had 1 more articles in the media than Global Cord Blood. MarketBeat recorded 3 mentions for Viemed Healthcare and 2 mentions for Global Cord Blood. Viemed Healthcare's average media sentiment score of 1.88 beat Global Cord Blood's score of 0.13 indicating that Viemed Healthcare is being referred to more favorably in the media.
Viemed Healthcare has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. Comparatively, Global Cord Blood has a beta of 0.16, indicating that its share price is 84% less volatile than the S&P 500.
Global Cord Blood received 339 more outperform votes than Viemed Healthcare when rated by MarketBeat users. Likewise, 74.51% of users gave Global Cord Blood an outperform vote while only 42.86% of users gave Viemed Healthcare an outperform vote.
Summary
Viemed Healthcare beats Global Cord Blood on 11 of the 16 factors compared between the two stocks.
Get Viemed Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for VMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viemed Healthcare Competitors List
Related Companies and Tools
